Rangeley Capital LLC Takes $235,000 Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Rangeley Capital LLC bought a new stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 107,000 shares of the biopharmaceutical company’s stock, valued at approximately $235,000. Rangeley Capital LLC owned 0.05% of Esperion Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ESPR. Geode Capital Management LLC raised its holdings in Esperion Therapeutics by 4.1% during the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock valued at $7,148,000 after buying an additional 171,609 shares in the last quarter. State Street Corp raised its position in Esperion Therapeutics by 2.7% in the third quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock worth $6,360,000 after purchasing an additional 99,802 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Esperion Therapeutics by 18.6% during the 4th quarter. JPMorgan Chase & Co. now owns 2,454,216 shares of the biopharmaceutical company’s stock worth $5,399,000 after buying an additional 385,099 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Esperion Therapeutics by 31.0% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 932,008 shares of the biopharmaceutical company’s stock valued at $2,050,000 after acquiring an additional 220,730 shares during the period. Finally, Wellington Management Group LLP boosted its position in Esperion Therapeutics by 66.8% in the third quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company’s stock valued at $995,000 after buying an additional 241,512 shares in the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Stock Performance

Esperion Therapeutics stock opened at $1.39 on Thursday. The stock has a market capitalization of $275.01 million, a price-to-earnings ratio of -2.17 and a beta of 1.04. The stock’s 50 day moving average price is $1.73 and its two-hundred day moving average price is $2.06. Esperion Therapeutics, Inc. has a 52-week low of $1.35 and a 52-week high of $3.94.

Analyst Ratings Changes

A number of brokerages have commented on ESPR. The Goldman Sachs Group began coverage on Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a report on Thursday, March 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Esperion Therapeutics in a research report on Friday, December 13th. JMP Securities restated a “market outperform” rating and set a $4.00 target price (down previously from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. Finally, Cantor Fitzgerald began coverage on shares of Esperion Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 target price for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $6.75.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.